Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
6.58 USD
2.49%
Market Closed
Updated:
Apr 30, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of REPL.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
REPL
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
REPL Competitors Multiples
Replimune Group Inc Competitors
Replimune Group Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Replimune Group Inc
NASDAQ:REPL
|
403.9m USD | 0 | -1.9 | -0 | -0 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.2B USD | 5.3 | 59.2 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148B USD | 5.2 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.1B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.6B USD | 7.4 | 24.7 | 16.3 | 17.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.2 | 35.3 | 21.4 | 26.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 14.5 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.6 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.2B USD | 3.2 | 26.9 | 14.5 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.5 | 45 | 61.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
